LEO Pharma strengthens leadership in medical dermatology with the appointment of Sophie Lamle as Chief Development Officer
3.11.2025 12:00:00 CET | LEO Pharma | Pressemeddelelse
- Sophie Lamle brings over 20 years of experience in the pharmaceutical industry, leading innovation, clinical development, and strategic transformation.
- Her appointment will further strengthen LEO Pharma’s Search & Develop innovation model, unlocking value with a focus on differentiated assets.
Ballerup, Denmark, November 3, 2025 – LEO Pharma, a leader in medical dermatology, today announces the appointment of Sophie Lamle, D.Phil, as new Executive Vice President (EVP) of Development. Sophie will join the Global Leadership Team and will play an instrumental role in further strengthening LEO Pharma's Search & Development model.
Sophie joins LEO Pharma from Teva Pharmaceuticals where she led the global R&D innovative medicines team, overseeing assets across Immunology and Neuroscience, from discovery through commercialization. She has more than 20 years of experience in the pharmaceutical industry driving innovation, clinical development and strategic transformation.
“I’m very much looking forward to becoming part of the LEO Pharma team, bringing purposeful innovation in medical dermatology. I’m passionate about making a fundamental difference for all those suffering from skin disease. The Search & Development model resonates strongly with me, as I am driven by forging strategic partnerships that accelerate asset progression and demonstrate value through differentiated clinical programs. I look forward to contributing to the next wave of growth at LEO Pharma,” says Sophie Lamle.
Sophie is originally from the United Kingdom and has a D.Phil. in Chemistry from the University of Oxford. Prior to her role at Teva, Sophie brings experience spanning a variety of roles in Vectura, Novartis Pharmaceuticals and IQVIA.
“Sophie is a very strong international profile and passionate about making a fundamental difference through innovation. With her experience and knowhow in partnerships and co-creation, as well as her strong leadership skills, she is the ideal candidate to lead Development in the next chapter of our journey,” says CEO Christophe Bourdon.
Sophie Lamle will join LEO Pharma as EVP of Development on December 1, 2025. Prior to her start, Mark Levick will conclude his tenure as interim EVP but will continue serving as a member of the Board of Directors and Chair of the Innovation Committee.
Kontakter
Jeppe IlkjærGlobal Communications
Tlf:+45 3050 2014JEILK@leo-pharma.comAbout LEO Pharma
LEO Pharma is a global leader in medical dermatology. We deliver innovative solutions for skin health, building on a century of experience with breakthrough medicines in healthcare. We are committed to making a fundamental difference in people’s lives, and our broad portfolio of treatments serves close to 100 million patients in over 70 countries annually. Headquartered in Denmark, LEO Pharma has a team of 4,000 people worldwide. LEO Pharma is co-owned by majority shareholder the LEO Foundation and, since 2021, Nordic Capital. For more information, visit www.leo-pharma.com
Følg pressemeddelelser fra LEO Pharma
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra LEO Pharma
LEO Pharma elects Henriette Mersebach to the Board of Directors14.8.2026 09:00:00 CEST | Pressemeddelelse
Henriette Mersebach will bring deep pharmaceutical R&D and innovation expertise to the Board
LEO Pharma announces key results of Phase 2 TRAPEDS-1 trial evaluating pharmacokinetics and safety of tralokinumab in children with moderate-to-severe atopic dermatitis9.7.2026 17:00:00 CEST | Pressemeddelelse
TRAPEDS-1 is a Phase 2 trial evaluating the pharmacokinetics and long-term safety of tralokinumab in children aged 6 to 11 years with moderate-to-severe atopic dermatitis.1 The pharmacokinetic profile was as expected and consistent with what has previously been observed with tralokinumab. Tralokinumab was generally well tolerated for up to 172 weeks of treatment, with no new safety signals identified.
LEO Pharma to showcase new data highlighting the burden and unmet needs in Chronic Hand Eczema at ESCD 2026 in Copenhagen25.6.2026 13:00:00 CEST | Pressemeddelelse
New data show that chronic hand eczema can disrupt working lives and school days, with many patients reporting sick leave from work and worsening of symptoms during everyday activities.1 Findings from the DELTA FORCE and DELTA TEEN phase 3 studies highlight the heavy burden of chronic hand eczema across the life course – from impaired work productivity in adults to an impact on school life in adolescents.1,2
LEO Pharma’s net-zero and emissions reduction targets validated by SBTi8.6.2026 09:00:00 CEST | Pressemeddelelse
LEO Pharma has achieved Science Based Targets initiative (SBTi) validation for its net-zero climate targets, including its ambition to reach net-zero greenhouse gas emissions by 2050, alongside near-term goals to reduce Scope 1 and 2 emissions by 63% and Scope 3 emissions by 37.5% by 2035 With its targets now validated, LEO Pharma is shifting from target-setting to implementation, advancing 15 prioritized initiatives in its Climate Transition Plan while emphasizing the connection between environmental health and patient care
LEO Pharma lancerer LOQTORZI® (toripalimab) på hjemmemarkedet i Danmark7.5.2026 09:00:00 CEST | Pressemeddelelse
LOQTORZI® (toripalimab) lanceres i kombination med standardkemoterapi i Danmark som en ny førstelinjebehandling til voksne patienter med recidiverende eller metastatisk nasopharyngeal cancer, som ikke kan behandles med kirurgi eller strålebehandling (R/M NPC).¹ LOQTORZI® har vist en dokumenteret overlevelsesgevinst og kan udgøre en potentiel ny standardbehandling for patienter med fremskreden R/M NPC.² Langtidsdata fra det kliniske JUPITER-02-studie viser, at LOQTORZI® i kombination med kemoterapi giver vedvarende og signifikante forbedringer i både samlet overlevelse (OS) og progressionsfri overlevelse (PFS) sammenlignet med kemoterapi alene¹, hvilket etablerer en ny behandlingsmulighed for patienter med R/M NPC Lanceringen styrker LEO Pharmas Critical Care-portefølje på hjemmemarkedet i Danmark og demonstrerer virksomhedens engagement i at bringe nye behandlinger til patienter – via en etableret specialiseret kommerciel platform til hospitaler.
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.
Besøg vores nyhedsrum